Through the use of case studies, experts in renal cell carcinoma (RCC) explored the latest recommendations in the systemic treatment of patients with clear cell or non–clear cell disease at the NCCN 2023 Annual Conference. This discussion utilized the presentation of 3 case scenarios on locally advanced kidney cancer, oligometastatic papillary RCC, and disease progression after initial treatment.
Larcher A, Dell’Oglio P, Fossati N, et al. When to perform preoperative chest computed tomography for renal cancer staging. BJU Int 2017;120:490–496.
Marconi L, Dabestani S, Lam TB, et al. Systematic review and meta-analysis of diagnostic accuracy of percutaneous renal tumour biopsy. Eur Urol 2016;69:660–673.
Borregales LD, Adibi M, Thomas AZ, et al. The role of neoadjuvant therapy in the management of locally advanced renal cell carcinoma. Ther Adv Urol 2016;8:130–141.
Powles T, Tomczak P, Park SH, et al. Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2022;23:1133–1144.
- Search Google Scholar
- Export Citation
, Powles T , Tomczak P , Park SH Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2022; 23: 1133– 1144. 36055304
Motzer RJ, Jonasch E, Agarwal N, et al. NCCN Clinical Practice Guidelines in Oncology: Kidney Cancer. Version 4.2023. Accessed May 4, 2023. Available at: https://www.nccn.org
McDermott DF, Lee JL, Bjarnason GA, et al. Open-label, single-arm phase II study of pembrolizumab monotherapy as first-line therapy in patients with advanced clear cell renal cell carcinoma. J Clin Oncol 2021;39:1020–1028.
Hasanov E, Yeboa DN, Tucker MD, et al. An interdisciplinary consensus on the management of brain metastases in patients with renal cell carcinoma. CA Cancer J Clin 2022;72:454–489.